Compare Fortinet Inc (FTNT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs BIO-TECHNE Corp — how do they compare? Fortinet Inc trades at $189.82 (market cap $138.88B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Fortinet Inc is far larger — about 12.2× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Fortinet Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fortinet Inc for 72 Days and BIO-TECHNE Corp for 63 Days on average.
| FTNT | TECH | |
|---|---|---|
Market Cap | $138.88B | $11.37B |
Volume | 3,857,161 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $191.27 | $72.61 |
52-Week Low | $75.23 | $43.31 |
Typical Hold Time | 72 Days | 63 Days |
Enterprise Value | $135.30B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $189.10, down 1.13% today but remains near recent highs with strong technical momentum. The cybersecurity leader demonstrates robust fundamentals with 28.17% net margins and consistent earnings beats, though valuation ratios appear elevated (P/E 66.88, P/S 18.81). Recent news highlights AI security demand driving platform growth, with the company scheduled to report Q3 2026 results on October 28.
Fortinet presents growth potential through cybersecurity market leadership and AI-driven demand, but faces valuation concerns and competitive pressures. The stock's technical strength and fundamental execution support upside, though high multiples require sustained growth to justify current levels. Key risks include execution missteps and market volatility amid elevated expectations.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
